Alnylam Pharmaceuticals, Inc.
ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products includeā¦ read more
Healthcare
Biotechnology
22 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$220.33
Price+7.21%
$14.81
1Y
Price
Market Cap
$29.482b
Large
Price/Earnings 3y Avg5y Avg
39.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+19.0%
EBITDA Margin+12.7%
Net Profit Margin+3.2%
Free Cash Flow Margin+19.0%
EBITDA Margin+12.7%
Net Profit Margin+3.2%
Free Cash Flow MarginRevenue
$4.804b
+29.4%
1y CAGR+39.2%
3y CAGR+48.4%
5y CAGREarnings
$807.988m
+157.5%
1y CAGR+135.7%
3y CAGR+117.0%
5y CAGREPS
$5.92
+154.1%
1y CAGR+133.0%
3y CAGR+115.3%
5y CAGRBook Value
$1.354b
$5.559b
Assets$4.205b
Liabilities$1.267b
DebtDebt to Assets
22.8%
1.1x
Debt to EBITDAFree Cash Flow
$542.543m
+16.6%
1y CAGR+335.9%
3y CAGR+278.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company